Etanercept conjugated with IRDye800CW exhibited a D/P ratio of 2.5:1. The measured concentration of the I-E conjugates was 1.01 mg/ml, which is close to the etanercept concentration (1 mg/ml) used in the labeling reaction. This suggests that there was no loss of etanercept during the reaction and purification process.
|Animal models||CIA rats|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Biodistribution of Etanercept to Tissues and Sites of Inflammation in Arthritic Rats
Chen X, et al. Drug Metab Dispos. 2015 Jun;43(6):898-907. PMID: 25834031.
Efficacy and safety of etanercept in chronic immune-mediated disease.
Murdaca G, et al. Expert Opin Drug Saf. 2014 May;13(5):649-61. PMID: 24654562.
AM-0902 is a potent, selective antagonist of TRPA1 with IC50s of 71 and 131 nM for rTRPA1 and hTRPA1, respectively.
BMS-813160 is the first dual CCR2/CCR5 antagonist to enter clinical development for cardiovascular.
BMS-986205 is a selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor.
VU6005649 is a CNS penetrant mGlu7/8 receptor agonist with EC50s of 0.65 μM and 2.6 μM for mGlu7 receptor and mGlu8 receptor, respectively.
TLR7-agonist-1 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.